Gastric cancer remains a critical public health issue globally, with new statistics from the National Cancer Center indicating about 514,000 new cases in ...

Cancer researchers found that patients on GLP-1s had significant risk reductions for 10 of 13 obesity-associated cancers.

Gastric cancer, commonly known as stomach cancer, is the fifth most common cancer globally and the fifth leading cause of ...

Nivolumab is approved for the treatment of 10 different cancer types including colorectal, non-small cell lung, head and neck ...

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

Background and objective Gastric cancer (GC) remains a prevalent and preventable disease, yet accurate early diagnostic ...

1 According to the American Cancer Society, gastric cancer accounts for 1.5% of all cancers in the United States. It is most common in people over 65 years of age, with a median diagnosis age of 68 ...

The FDA has approved subcutaneous nivolumab and hyaluronidase-nvhy (Opdivo Qvantig) to treat a range of solid tumor malignancies.

hepatocellular carcinoma, gastric or gastroesophageal junction carcinoma, nasopharyngeal carcinoma, renal cell carcinoma, cervical cancer, triple-negative breast cancer, ovarian cancer, endometrial ...

San Mateo, California Monday, December 30, 2024, 18:00 Hrs [IST] ...